Leidner, Rom S.

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 938

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Papadopoulos, K. P., Johnson, M. L., Lockhart, A. C., Moore, K., Falchook, G. S., Formenti, S. C., Naing, A., Carvajal, R. D., Rosen, L. S., Weiss, G. J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 66

Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.

Foster, C. C., Kochanny, S., Khattri, A., Acharya, R., Dekker, A., Tan, Y.-H. C., Klema, E., Brisson, R. J., Saloura, V., Pearson, A. T., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersHead and Neck Cancer Studies

Cited by 28

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

Tran, E., Urba, W. J., & Leidner, R. S. (2022) · New England Journal of Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 24